136 related articles for article (PubMed ID: 29500843)
1. Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Tamura K; Kodaira M; Shimizu C; Yonemori K; Yunokawa M; Shimomura A; Kobayashi T; Nakano K; Tomomatsu J; Ito Y; Tanaka J; Kuriki H; Gu Z; Takahashi S
Cancer Sci; 2018 May; 109(5):1592-1601. PubMed ID: 29500843
[TBL] [Abstract][Full Text] [Related]
2. Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Juric D; Krop I; Ramanathan RK; Wilson TR; Ware JA; Sanabria Bohorquez SM; Savage HM; Sampath D; Salphati L; Lin RS; Jin H; Parmar H; Hsu JY; Von Hoff DD; Baselga J
Cancer Discov; 2017 Jul; 7(7):704-715. PubMed ID: 28331003
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Dickler MN; Saura C; Richards DA; Krop IE; Cervantes A; Bedard PL; Patel MR; Pusztai L; Oliveira M; Cardenas AK; Cui N; Wilson TR; Stout TJ; Wei MC; Hsu JY; Baselga J
Clin Cancer Res; 2018 Sep; 24(18):4380-4387. PubMed ID: 29793946
[No Abstract] [Full Text] [Related]
5. Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Dent S; Cortés J; Im YH; Diéras V; Harbeck N; Krop IE; Wilson TR; Cui N; Schimmoller F; Hsu JY; He J; De Laurentiis M; Sousa S; Drullinsky P; Jacot W
Ann Oncol; 2021 Feb; 32(2):197-207. PubMed ID: 33186740
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Saura C; Hlauschek D; Oliveira M; Zardavas D; Jallitsch-Halper A; de la Peña L; Nuciforo P; Ballestrero A; Dubsky P; Lombard JM; Vuylsteke P; Castaneda CA; Colleoni M; Santos Borges G; Ciruelos E; Fornier M; Boer K; Bardia A; Wilson TR; Stout TJ; Hsu JY; Shi Y; Piccart M; Gnant M; Baselga J; de Azambuja E
Lancet Oncol; 2019 Sep; 20(9):1226-1238. PubMed ID: 31402321
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
Grinshpun A; Ren S; Graham N; DeMeo MK; Wrabel E; Carter J; Tayob N; Pereslete A; Hamilton E; Juric D; Mayer EL; Tolaney SM; Krop IE; Metzger O
ESMO Open; 2024 Jun; 9(6):103465. PubMed ID: 38833970
[TBL] [Abstract][Full Text] [Related]
8. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in
Pascual J; Lim JSJ; Macpherson IR; Armstrong AC; Ring A; Okines AFC; Cutts RJ; Herrera-Abreu MT; Garcia-Murillas I; Pearson A; Hrebien S; Gevensleben H; Proszek PZ; Hubank M; Hills M; King J; Parmar M; Prout T; Finneran L; Malia J; Swales KE; Ruddle R; Raynaud FI; Turner A; Hall E; Yap TA; Lopez JS; Turner NC
Cancer Discov; 2021 Jan; 11(1):92-107. PubMed ID: 32958578
[TBL] [Abstract][Full Text] [Related]
9. POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Baird RD; van Rossum AGJ; Oliveira M; Beelen K; Gao M; Schrier M; Mandjes IAM; Garcia-Corbacho J; Vallier AL; Dougall G; van Werkhoven E; Linossi C; Kumar S; van Tinteren H; Callari M; Beddowes E; Perez-Garcia JM; Rosing H; Platte E; Nederlof P; Schot M; de Vries Schultink A; Bernards R; Saura C; Gallagher W; Cortès J; Caldas C; Linn SC
Clin Cancer Res; 2019 Nov; 25(22):6598-6605. PubMed ID: 31439579
[TBL] [Abstract][Full Text] [Related]
10. Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Moore HM; Savage HM; O'Brien C; Zhou W; Sokol ES; Goldberg ME; Metcalfe C; Friedman LS; Lackner MR; Wilson TR
Mol Cancer Ther; 2020 Jan; 19(1):292-303. PubMed ID: 31534012
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Taselisib in
Krop IE; Jegede OA; Grilley-Olson JE; Lauring JD; Mitchell EP; Zwiebel JA; Gray RJ; Wang V; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Kono SA; Ford JM; Garcia AA; Sui XD; Siegel RD; Slomovitz BM; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
JCO Precis Oncol; 2022 Feb; 6():e2100424. PubMed ID: 35138919
[TBL] [Abstract][Full Text] [Related]
12. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with
Jhaveri K; Chang MT; Juric D; Saura C; Gambardella V; Melnyk A; Patel MR; Ribrag V; Ma CX; Aljumaily R; Bedard PL; Sachdev JC; Dunn L; Won H; Bond J; Jones S; Savage HM; Scaltriti M; Wilson TR; Wei MC; Hyman DM
Clin Cancer Res; 2021 Jan; 27(2):447-459. PubMed ID: 33148674
[TBL] [Abstract][Full Text] [Related]
13. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
14. Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Lopez S; Schwab CL; Cocco E; Bellone S; Bonazzoli E; English DP; Schwartz PE; Rutherford T; Angioli R; Santin AD
Gynecol Oncol; 2014 Nov; 135(2):312-7. PubMed ID: 25172762
[TBL] [Abstract][Full Text] [Related]
15. SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Langer CJ; Redman MW; Wade JL; Aggarwal C; Bradley JD; Crawford J; Stella PJ; Knapp MH; Miao J; Minichiello K; Herbst RS; Kelly K; Gandara DR; Papadimitrakopoulou VA
J Thorac Oncol; 2019 Oct; 14(10):1839-1846. PubMed ID: 31158500
[TBL] [Abstract][Full Text] [Related]
16. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
17. Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Kaklamani VG; Richardson AL; Arteaga CL
Oncologist; 2019 Mar; 24(3):305-312. PubMed ID: 30651399
[TBL] [Abstract][Full Text] [Related]
18. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR
Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268
[TBL] [Abstract][Full Text] [Related]
19. [Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021].
Mezni E; Sabatier R; Goncalves A; Vicier C
Bull Cancer; 2022 Feb; 109(2):216-225. PubMed ID: 35115114
[TBL] [Abstract][Full Text] [Related]
20. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR
Lehmann BD; Abramson VG; Sanders ME; Mayer EL; Haddad TC; Nanda R; Van Poznak C; Storniolo AM; Nangia JR; Gonzalez-Ericsson PI; Sanchez V; Johnson KN; Abramson RG; Chen SC; Shyr Y; Arteaga CL; Wolff AC; Pietenpol JA;
Clin Cancer Res; 2020 May; 26(9):2111-2123. PubMed ID: 31822498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
